ß1-integrin is a crucial regulator of the exocytotic machinery in pancreatic beta-cells, affecting insulin secretion and integrin trafficking.

α1-整合素是胰腺β细胞胞吐机制的重要调节因子，影响胰岛素分泌和整合素运输。

• 批准号: RGPIN-2017-04658
• 负责人: Wang, Rennian
• 金额: $ 2.48万
• 依托单位: University of Western Ontario
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=629373
• 关键词: integrin; crucial; regulator; exocytotic; machinery

The discovery of insulin in 1921 by Banting and Best laid the foundation for the modern management of diabetes mellitus, a disease that affects millions of Canadians and costs our healthcare system more than $17 billion annually. However, insulin treatment cannot cure diabetes and will not prevent the secondary complications, which are responsible for the devastating morbidity and mortality of this disease. Replacement of insulin-producing (beta) cells through a cell-based therapy (e.g. pancreatic islet transplantation or a bioartificial endocrine pancreas) has the best chance to prevent, reverse or stabilize these complications. However, the scarcity of islets and limitations in our knowledge of the factors influencing islet biology present a major obstacle to the adoption of cell-based therapies as a routine treatment. Advancement in this field requires a thorough understanding of the factors that regulate growth of the islet beta cells and maintain their viability and function.

1921年，Banting和Best发现了胰岛素，为糖尿病的现代管理奠定了基础。糖尿病是一种影响数百万加拿大人的疾病，每年花费我们的医疗系统超过170亿美元。然而，胰岛素治疗不能治愈糖尿病，也不能预防继发性并发症，而继发性并发症是导致这种疾病毁灭性的发病率和死亡率的原因。通过基于细胞的治疗(如胰岛移植或生物人工内分泌胰腺)替换产生胰岛素的(β)细胞是预防、逆转或稳定这些并发症的最好机会。然而，胰岛的稀缺和我们对影响胰岛生物学的因素的了解的局限性是采用基于细胞的治疗作为常规治疗的主要障碍。这一领域的进展需要对调节胰岛β细胞生长和维持其活性和功能的因素有深入的了解。